Abstract
Prophylactic human papillomavirus (HPV) vaccination was implemented in the UK in 2008 for girls aged 12–13 years. There is a ‘catch‐up’ programme for girls up to the age of 18 years. The bivalent vaccine (Cervarix®), covering HPV 16 and 18 was chosen for the first 3 years of the UK vaccination programme. Surveillance is essential to evaluate long‐term effectiveness and answer the remaining questions. Learning objectives: To be aware of the implementation of HPV vaccination in the UK. To be aware of remaining unanswered questions and the need for surveillance. To understand the importance of key messages for girls being vaccinated against HPV. Ethical issues: Will HPV vaccination of girls in the UK be acceptable to everyone? Have the key public health messages been clearly stated and understood? Addressing the major burden of HPV‐related neoplasia in developing countries is an ethical imperative. Please cite this article as: Fiander A. Prophylactic human papillomavirus vaccination update. The Obstetrician & Gynaecologist 2009;11:133–135.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
